CA
NZ
UK
AU
IND
US
ResMed Inc. filed a current report on Form 8-K on August 17, 2026, disclosing the dismissal of KPMG LLP as its independent registered public accounting firm, the appointment of PricewaterhouseCoopers LLP as its successor auditor, and the planned retirement of a board director.
NNN REIT, Inc. filed a Form 8-K on August 17, 2026, disclosing the appointment of two new directors to its Board and the planned retirement of a current director, effective at staggered dates in 2026 and 2027.
Starz Entertainment Corp. filed a Form 8-K on August 17, 2026, disclosing that on August 12, 2026, it entered into Amendment No. 1 and Incremental Amendment to its existing credit agreement, increasing revolving credit commitments by $33 million and adding $67 million in incremental …
MetLife, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 17, 2026, disclosing the declaration of preferred stock dividends across four series of its preferred equity.
Black Hills Corporation filed a Form 8-K with the SEC on August 17, 2026, providing historical financial statements of NorthWestern Energy Group, Inc. and unaudited pro forma combined financial information in connection with the companies' pending all-stock merger.
Lumentum Holdings Inc. filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on August 17, 2026, covering the fiscal year ended June 27, 2026.
A Form 4 filed with the SEC on August 17, 2026, disclosed that Anthony Ibarguen, a director of Insight Enterprises Inc (NASDAQ:NSIT), sold 4,000 shares of common stock on August 13, 2026.
SimilarWeb Ltd. Chief Executive Officer filed a Form 4 on August 17, 2026, disclosing the exercise of stock options and the sale of ordinary shares on August 13 and August 14, 2026.
A Form 4 filed on August 17, 2026 reports that John Cox, CEO and President of Dyne Therapeutics, Inc. (NASDAQ:DYN), disposed of 4,986 shares of common stock on August 13, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units.
A Form 4 filed on August 17, 2026, disclosed that Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), sold 1,556 shares of common stock on August 13, 2026, to satisfy tax withholding obligations tied to vesting restricted stock units.
Please wait processing your request...